Benefits of Danazol Treatment in Patients With Hemophilia A (Classic Hemophilia)

• Published in: JAMA : the journal of the American Medical Association Vol. 253; no. 8; pp. 1151 - 1153
• Main Authors: Gralnick, Harvey R, Maisonneuve, Pascal, Sultan, Yvette, Rick, Margaret E
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 22-02-1985
• Subjects: Adult; Blood Transfusion; Danazol - therapeutic use; Factor VIII - metabolism; Hemophilia A - blood; Hemophilia A - drug therapy; Humans; Male; Pregnadienes - therapeutic use; Time Factors
• ISSN: 0098-7484; 1538-3598
• DOI: 10.1001/jama.1985.03350320075020

Danazol, an attenuated androgen, was given intermittently to three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.(JAMA 1985;253:1151-1153)